The Latin America, Middle East and Africa Metastatic Cancer Drugs Market would witness market growth of 11.3% CAGR during the forecast period (2023-2030).
The market has expanded due to substantial developments in metastatic cancer research & development. Ongoing research has resulted in a greater understanding of the molecular mechanisms underlying metastatic cancer, identifying novel targets, and the development of innovative therapeutics. The discovery and development of targeted medicines and personalized medical methods have been helped by technological developments such as genomics, proteomics, and high-throughput screening techniques.
Increased use of targeted medicines, which explicitly target molecules and pathways implicated in metastatic cancer progression, has also become an essential therapy component. Trastuzumab, pertuzumab, and CDK4/6 inhibitors, among other medications, have demonstrated notable success in particular metastatic breast, ovarian, and prostate cancer subtypes. In addition, immunotherapies that use the immune system to combat cancer cells, such as immune checkpoint inhibitors, have shown promise in subgroups of patients with breast, colorectal, and prostate cancer. The creation and acceptance of these immunotherapies and targeted treatments have increased treatment options and fueled market expansion.
According to data from the International Agency for Research on Cancer's (IARC) GLOBOCAN 2018 database, the estimated results of 36 cancer types available from 47 countries in WHO's African region (AFRO) revealed that 811,200 new cancer cases (4.5% of the total world) and 534,000 cancer deaths (7.3% of the total world) were reported in AFRO countries in 2018. The estimated cancer burden in AFRO countries is mostly due to breast cancer, which accounts for 27.7% of all cancer cases, trailed by cervical cancer, which accounts for 19.6% of all cases. When taken as a whole, this is the most prevalent in African girls. Prostate cancer was the most frequent cancer in African men, accounting for 18.1% of all cases, followed by liver cancer (9.7% of all cases) and colon cancer (6.9% of all cases). In terms of pediatric cancer survival rates, they are as low as 20% in African children and as high as 80% in high-income countries. This high incidence of cancer cases raises the need for metastatic cancer drugs in LAMEA region.
The Brazil market dominated the LAMEA Metastatic Cancer Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,552.3 million by 2030. The Argentina market is showcasing a CAGR of 11.9% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 11% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Indication, the market is segmented into Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer and Melanoma & Others. Based on Therapy, the market is segmented into Targeted Therapy, Immunotherapy, Hormonal Therapy and Chemotherapy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Metastatic Cancer Drugs Market is Projected to reach USD 115.6 Billion by 2030, at a CAGR of 7.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, Inc. and Sanofi S.A.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Providers
By Indication
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma & Others
By Therapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- Chemotherapy
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Bristol Myers Squibb Company
- Merck & Co., Inc.
- AstraZeneca PLC
- Novartis AG
- Eli Lilly And Company
- Pfizer, Inc.
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Amgen, Inc.
- Sanofi S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Metastatic Cancer Drugs Market, by Distribution Channel
1.4.2 LAMEA Metastatic Cancer Drugs Market, by Indication
1.4.3 LAMEA Metastatic Cancer Drugs Market, by Therapy
1.4.4 LAMEA Metastatic Cancer Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Approvals & Trials
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2019, Jul – 2023, Apr) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. LAMEA Metastatic Cancer Drugs Market by Distribution Channel
5.1 LAMEA Hospital Pharmacies Market by Country
5.2 LAMEA Drug Store & Retail Pharmacies Market by Country
5.3 LAMEA Online Providers Market by Country
Chapter 6. LAMEA Metastatic Cancer Drugs Market by Indication
6.1 LAMEA Breast Cancer Market by Country
6.2 LAMEA Lung Cancer Market by Country
6.3 LAMEA Prostate Cancer Market by Country
6.4 LAMEA Colorectal Cancer Market by Country
6.5 LAMEA Melanoma & Others Market by Country
Chapter 7. LAMEA Metastatic Cancer Drugs Market by Therapy
7.1 LAMEA Targeted Therapy Market by Country
7.2 LAMEA Immunotherapy Market by Country
7.3 LAMEA Hormonal Therapy Market by Country
7.4 LAMEA Chemotherapy Market by Country
Chapter 8. LAMEA Metastatic Cancer Drugs Market by Country
8.1 Brazil Metastatic Cancer Drugs Market
8.1.1 Brazil Metastatic Cancer Drugs Market by Distribution Channel
8.1.2 Brazil Metastatic Cancer Drugs Market by Indication
8.1.3 Brazil Metastatic Cancer Drugs Market by Therapy
8.2 Argentina Metastatic Cancer Drugs Market
8.2.1 Argentina Metastatic Cancer Drugs Market by Distribution Channel
8.2.2 Argentina Metastatic Cancer Drugs Market by Indication
8.2.3 Argentina Metastatic Cancer Drugs Market by Therapy
8.3 UAE Metastatic Cancer Drugs Market
8.3.1 UAE Metastatic Cancer Drugs Market by Distribution Channel
8.3.2 UAE Metastatic Cancer Drugs Market by Indication
8.3.3 UAE Metastatic Cancer Drugs Market by Therapy
8.4 Saudi Arabia Metastatic Cancer Drugs Market
8.4.1 Saudi Arabia Metastatic Cancer Drugs Market by Distribution Channel
8.4.2 Saudi Arabia Metastatic Cancer Drugs Market by Indication
8.4.3 Saudi Arabia Metastatic Cancer Drugs Market by Therapy
8.5 South Africa Metastatic Cancer Drugs Market
8.5.1 South Africa Metastatic Cancer Drugs Market by Distribution Channel
8.5.2 South Africa Metastatic Cancer Drugs Market by Indication
8.5.3 South Africa Metastatic Cancer Drugs Market by Therapy
8.6 Nigeria Metastatic Cancer Drugs Market
8.6.1 Nigeria Metastatic Cancer Drugs Market by Distribution Channel
8.6.2 Nigeria Metastatic Cancer Drugs Market by Indication
8.6.3 Nigeria Metastatic Cancer Drugs Market by Therapy
8.7 Rest of LAMEA Metastatic Cancer Drugs Market
8.7.1 Rest of LAMEA Metastatic Cancer Drugs Market by Distribution Channel
8.7.2 Rest of LAMEA Metastatic Cancer Drugs Market by Indication
8.7.3 Rest of LAMEA Metastatic Cancer Drugs Market by Therapy
Chapter 9. Company Profiles
9.1 Bristol Myers Squibb Company
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Merck & Co., Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.6 SWOT Analysis
9.3 AstraZeneca PLC
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 SWOT Analysis
9.4 Novartis AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.6 SWOT Analysis
9.5 Eli Lilly And Company
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.6 SWOT Analysis
9.6 Pfizer, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional & Segmental Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.6 SWOT Analysis
9.7 F. Hoffmann-La Roche Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials & Approvals:
9.7.6 SWOT Analysis
9.8 Johnson & Johnson
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental &Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.6 SWOT Analysis
9.9 Amgen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expenses
9.9.5 SWOT Analysis
9.10. Sanofi S.A.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.6 SWOT Analysis
TABLE 1 LAMEA Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Metastatic Cancer Drugs Market
TABLE 4 Product Launches And Product Expansions– Metastatic Cancer Drugs Market
TABLE 5 Acquisition and Mergers– Metastatic Cancer Drugs Market
TABLE 6 Approvals & Trials– Metastatic Cancer Drugs Market
TABLE 7 LAMEA Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 LAMEA Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 9 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 11 LAMEA Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 LAMEA Drug Store & Retail Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 13 LAMEA Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 14 LAMEA Online Providers Market by Country, 2023 - 2030, USD Million
TABLE 15 LAMEA Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 16 LAMEA Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 17 LAMEA Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 18 LAMEA Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 19 LAMEA Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 21 LAMEA Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 22 LAMEA Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 23 LAMEA Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 25 LAMEA Melanoma & Others Market by Country, 2019 - 2022, USD Million
TABLE 26 LAMEA Melanoma & Others Market by Country, 2023 - 2030, USD Million
TABLE 27 LAMEA Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 28 LAMEA Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 29 LAMEA Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 30 LAMEA Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 31 LAMEA Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 32 LAMEA Immunotherapy Market by Country, 2023 - 2030, USD Million
TABLE 33 LAMEA Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 34 LAMEA Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 35 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 36 LAMEA Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 37 LAMEA Metastatic Cancer Drugs Market by Country, 2019 - 2022, USD Million
TABLE 38 LAMEA Metastatic Cancer Drugs Market by Country, 2023 - 2030, USD Million
TABLE 39 Brazil Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 40 Brazil Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 41 Brazil Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 Brazil Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 Brazil Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 44 Brazil Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 45 Brazil Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 46 Brazil Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 47 Argentina Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 48 Argentina Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 49 Argentina Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 Argentina Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Argentina Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 52 Argentina Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 53 Argentina Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 54 Argentina Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 55 UAE Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 56 UAE Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 57 UAE Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 UAE Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 UAE Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 60 UAE Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 61 UAE Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 62 UAE Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 63 Saudi Arabia Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 64 Saudi Arabia Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 65 Saudi Arabia Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 Saudi Arabia Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Saudi Arabia Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 68 Saudi Arabia Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 69 Saudi Arabia Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 70 Saudi Arabia Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 71 South Africa Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 72 South Africa Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 73 South Africa Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 South Africa Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 South Africa Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 76 South Africa Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 77 South Africa Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 78 South Africa Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 79 Nigeria Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 80 Nigeria Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 81 Nigeria Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Nigeria Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Nigeria Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 84 Nigeria Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 85 Nigeria Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 86 Nigeria Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 87 Rest of LAMEA Metastatic Cancer Drugs Market, 2019 - 2022, USD Million
TABLE 88 Rest of LAMEA Metastatic Cancer Drugs Market, 2023 - 2030, USD Million
TABLE 89 Rest of LAMEA Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 90 Rest of LAMEA Metastatic Cancer Drugs Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 91 Rest of LAMEA Metastatic Cancer Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 92 Rest of LAMEA Metastatic Cancer Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 93 Rest of LAMEA Metastatic Cancer Drugs Market by Therapy, 2019 - 2022, USD Million
TABLE 94 Rest of LAMEA Metastatic Cancer Drugs Market by Therapy, 2023 - 2030, USD Million
TABLE 95 Key Information – Bristol Myers Squibb Company
TABLE 96 KEY INFORMATION - Merck & Co., Inc.
TABLE 97 KEY INFORMATION – AstraZeneca PLC
TABLE 98 Key Information – Novartis AG
TABLE 99 Key Information – Eli Lilly And Company
TABLE 100 Key Information – Pfizer, Inc.
TABLE 101 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 102 Key Information – Johnson & Johnson
TABLE 103 Key Information – Amgen, Inc.
TABLE 104 Key Information – Sanofi S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Metastatic Cancer Drugs Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Metastatic Cancer Drugs Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2019, Jul – 2023, Apr) Leading Players
FIG 7 Porter’s Five Forces Analysis - Metastatic Cancer Drugs Market
FIG 8 LAMEA Metastatic Cancer Drugs Market share by Distribution Channel, 2022
FIG 9 LAMEA Metastatic Cancer Drugs Market share by Distribution Channel, 2030
FIG 10 LAMEA Metastatic Cancer Drugs Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 LAMEA Metastatic Cancer Drugs Market share by Indication, 2022
FIG 12 LAMEA Metastatic Cancer Drugs Market share by Indication, 2030
FIG 13 LAMEA Metastatic Cancer Drugs Market by Indication, 2019 - 2030, USD Million
FIG 14 LAMEA Metastatic Cancer Drugs Market share by Therapy, 2022
FIG 15 LAMEA Metastatic Cancer Drugs Market share by Therapy, 2030
FIG 16 LAMEA Metastatic Cancer Drugs Market by Therapy, 2019 - 2030, USD Million
FIG 17 LAMEA Metastatic Cancer Drugs Market share by Country, 2022
FIG 18 LAMEA Metastatic Cancer Drugs Market share by Country, 2030
FIG 19 LAMEA Metastatic Cancer Drugs Market by Country, 2019 - 2030, USD Million
FIG 20 SWOT Analysis: Bristol Myers Squibb Company
FIG 21 Swot Analysis: Merck & Co., Inc.
FIG 22 Swot Analysis: AstraZeneca PLC
FIG 23 SWOT Analysis: Novartis AG
FIG 24 Swot Analysis: Eli Lilly And Company
FIG 25 Recent strategies and developments: Pfizer, Inc.
FIG 26 Swot Analysis: Pfizer, Inc.
FIG 27 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 28 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 29 Swot Analysis: Johnson & Johnson
FIG 30 Swot Analysis: Amgen, Inc.
FIG 31 Swot Analysis: Sanofi S.A.